Genomically Guided Breast Radiation Therapy: A Review of the Current Data and Future Directions.

Autor:	Liveringhouse CL; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Washington IR; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Diaz R; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Jimenez RB; Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts., Harris EE; Department of Radiation Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio., Rabinovitch R; Department of Radiation Oncology, University of Colorado Cancer Center, Aurora, Colorado., Woodward WA; Department of Radiation Oncology, UT MD Anderson Cancer Center, Houston, Texas., Torres-Roca JF; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Ahmed KA; Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Jazyk:	angličtina
Zdroj:	Advances in radiation oncology [Adv Radiat Oncol] 2021 May 28; Vol. 6 (4), pp. 100731. Date of Electronic Publication: 2021 May 28 (Print Publication: 2021).
DOI:	10.1016/j.adro.2021.100731
Abstrakt:	Purpose: To highlight the current evidence and the limitations in data to support a personalized approach in breast oncology radiation therapy management and define steps needed for clinical implementation. Methods and Materials: A critical review of the current literature on the use of genomics in breast radiation therapy was undertaken by a group of breast radiation oncologists to discuss current data, future directions, and challenges. Results: A summary of the existing data, ongoing clinical trials, and future directions is provided. The authors note many groups have developed radiation-specific genomic assays, which demonstrate promise in prediction of local control and benefit from radiation therapy; however, prospective validation of their utility is needed. Limitations continue to exist in our understanding of tumor biology and how it can be integrated into clinical practice. Conclusions: Given the relative ubiquity of breast radiation therapy, the variety of dose and fractionation approaches, and the current data to support a personalized approach, it is our belief that the delivery of breast radiation therapy is uniquely poised for a genomically personalized radiation therapy approach. Prospective clinical trials implementing genomic signatures are needed at this time to advance the field. (© 2021 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu